Examkin

Question

Difficulty: HardStudy Design

A pulmonology research consortium is planning a clinical trial to evaluate a novel inhaled bronchodilator for the symptomatic management of moderate, stable chronic obstructive pulmonary disease (COPD). To maximize statistical efficiency due to funding constraints and a limited patient pool, the investigators choose a design where each enrolled participant is randomized to receive either the novel bronchodilator or a matching placebo for four weeks. Subsequently, following a two-week intervention-free interval, participants who initially received the active drug will receive the placebo, and those who received the placebo will receive the active drug for another four weeks. The primary outcome is the mean change in daily breathlessness scores.

Which of the following conditions is an essential requirement for this specific study design to yield valid results?

  1. A
    The underlying disease process must demonstrate a continuous and predictable clinical decline throughout the duration of the trial.
  2. The physiological effects of the initial therapeutic assignment must be completely resolved before the second evaluation period begins.Answer
  3. C
    The primary outcome measure must consist of a definitive, irreversible endpoint such as acute exacerbation requiring mechanical ventilation.
  4. D
    The statistical analysis must incorporate an external, unexposed control group to adequately determine the baseline population risk.
  5. E
    The final statistical model must adjust for time-invariant baseline covariates, such as patient biological sex and genetic history.

Answer

The physiological effects of the initial therapeutic assignment must be completely resolved before the second evaluation period begins.
The clinical vignette describes a crossover randomized controlled trial. In this study design, each participant receives a sequence of different treatments, effectively serving as their own control. A unique and critical vulnerability of this design is the 'carryover effect,' which occurs when the physiological, pharmacological, or psychological effects of the first treatment persist into the second treatment phase, thereby confounding the results. To mitigate this threat and ensure internal validity, an adequate 'washout period' (the intervention-free interval described in the stem) must be implemented. This period must be sufficiently long to ensure that the physiological effects of the initial therapeutic assignment have completely resolved and the patient has returned to their baseline state before the second evaluation period begins.

Step-by-Step Solution

1
Identify the specific study design described in the clinical vignette.
The scenario describes a crossover randomized controlled trial, as each patient receives both the active drug and the placebo sequentially, separated by an intervention-free interval.
Recognizing the study design is the necessary first step to understanding its inherent methodological strengths and weaknesses.
2
Determine the unique threats to internal validity associated with this study design.
The primary threat is the 'carryover effect,' where the physiological or psychological impacts of the first treatment persist into the second treatment period.
Understanding what can compromise the data allows investigators to implement specific design requirements to protect validity.
3
Evaluate the options to identify the requirement that directly mitigates this specific threat.
The requirement that all effects of the initial therapy must be completely resolved describes the purpose of the 'washout period' (the intervention-free interval).
If the effects are not completely resolved, the patient's baseline for the second phase is altered, severely biasing the final within-subject comparison.

Key Concept

Crossover Study Design Requirements and Limitations
Estimated Time:1m 30s
Rate this question

Topics

Study Design

More questions from this topic